Correlation Between Cyclacel Pharmaceuticals and InMed Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Cyclacel Pharmaceuticals and InMed Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cyclacel Pharmaceuticals and InMed Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cyclacel Pharmaceuticals and InMed Pharmaceuticals, you can compare the effects of market volatilities on Cyclacel Pharmaceuticals and InMed Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cyclacel Pharmaceuticals with a short position of InMed Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cyclacel Pharmaceuticals and InMed Pharmaceuticals.

Diversification Opportunities for Cyclacel Pharmaceuticals and InMed Pharmaceuticals

-0.14

Correlation Coefficient

Cyclacel Pharmaceuticals  InMed Pharmaceuticals

Good diversification

The 3 months correlation between Cyclacel and InMed is -0.14. Overlapping area represents the amount of risk that can be diversified away by holding Cyclacel Pharmaceuticals and InMed Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on InMed Pharmaceuticals and Cyclacel Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cyclacel Pharmaceuticals are associated (or correlated) with InMed Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of InMed Pharmaceuticals has no effect on the direction of Cyclacel Pharmaceuticals i.e., Cyclacel Pharmaceuticals and InMed Pharmaceuticals go up and down completely randomly.

Pair Corralation between Cyclacel Pharmaceuticals and InMed Pharmaceuticals

Assuming the 90 days horizon Cyclacel Pharmaceuticals is expected to generate 3.18 times more return on investment than InMed Pharmaceuticals. However, Cyclacel Pharmaceuticals is 3.18 times more volatile than InMed Pharmaceuticals. It trades about 0.18 of its potential returns per unit of risk. InMed Pharmaceuticals is currently generating about -0.19 per unit of risk. If you would invest  690.00  in Cyclacel Pharmaceuticals on December 5, 2024 and sell it today you would earn a total of  234.00  from holding Cyclacel Pharmaceuticals or generate 33.91% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Cyclacel Pharmaceuticals  vs.  InMed Pharmaceuticals

Cyclacel Pharmaceuticals

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cyclacel Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent fundamental indicators, Cyclacel Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.

InMed Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days InMed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Cyclacel Pharmaceuticals and InMed Pharmaceuticals

The main advantage of trading using opposite Cyclacel Pharmaceuticals and InMed Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cyclacel Pharmaceuticals position performs unexpectedly, InMed Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InMed Pharmaceuticals will offset losses from the drop in InMed Pharmaceuticals' long position.

The idea behind Cyclacel Pharmaceuticals and InMed Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.